Trial intelligence / Profile preview

Pegylated interferon alfa-2a to control virological rebound after HAART interruption in chronic HIV infection

2011-004693-29Phase 2Terminated

Sponsor
National Institute for Infectious Diseases Lazzaro Spallanzani
Start
Mar 2012
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

A Phase 2 trial of peginterferon alfa-2a in human immunodeficiency virus infection (HIV), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Started Mar 2012; status: terminated.

02

Drugs

peginterferon alfa-2a
03

Conditions

human immunodeficiency virus infection (HIV)

Beyond the preview

Go deeper on 2011-004693-29.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-004693-29.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call